STAT |
Sanofi and Regeneron encounter more payer resistance over new eczema drug — this time, in the UK
STAT nce again, Sanofi (SNY 1) and Regeneron Pharmaceuticals (REGN 2) are running into roadblocks trying to win over payers with their new drug for severe eczema. The latest frustration is occurring in the U.K., where a government watchdog decided the drug … Sanofi makes double EU filing for cancer and asthma drugs Sanofi responds to draft NICE guidance for its innovative atopic dermatitis drug Dupixent® ? (dupilumab)[i] Regeneron And Sanofi Say EMA Accepts For Review Application For DUPIXEN |
